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Summary
HEK293T cells overexpressing divalent metal trans-
porter-1 (DMT1) were established to screen for small-
molecule inhibitors of iron uptake. Using a fluores-
cence-based assay, we tested 2000 known bioactive
compounds to find 3 small molecules that potently
block ferrous iron uptake. One of the inhibitors, ebse-
len, is a seleno compound used in clinical trials as
a protective agent against ischemic stroke. Ebselen in-
hibited Fe(II) uptake (IC50 ofw0.22 mM), but did not in-
fluence Fe(III) transport or DMT1-mediatedmanganese
uptake. An unrelated antioxidant, pyrrolidine dithio-
barbamate (PDTC), also inhibited DMT1 activity (IC50
ofw1.54 mM). Both ebselen and PDTC increased cellu-
lar levels of reduced glutathione. These observations
indicate that Fe(II) transport by DMT1 can be modu-
lated by cellular redox status and suggest that ebselen
may act therapeutically to limit iron-catalyzed damage
due to transport inhibition.
Introduction
Small molecules can help to define biological pathways
by inhibiting protein function to discover the factors
involved in dynamic cellular processes. In particular,
studies of membrane transport by carriers and channels
have been significantly advanced by the use of pharma-
cological inhibitors to analyze transport mechanisms.
Recent developments in the area of iron transport have
led to the discovery of several novel membrane trans-
porters and a new understanding of the regulation of iron
absorption [1, 2]. Unfortunately, this area of research
has been hampered by the lack of pharmacological re-
agents to probe the underlying molecular mechanisms
involved in these processes. To identify small-molecule
inhibitors of iron transport, we previously established
a cell-based screening assay that takes advantage of
iron-induced quenching of calcein fluorescence [3].
Using this approach, we discovered ten inhibitors of
nontransferrin bound iron (NTBI) uptake [4]. Two other
pathways of iron uptake are known to be mediated by
divalent metal transporter-1 (DMT1). DMT1 is the trans-
porter responsible for dietary iron absorption across the
apical membrane of intestinal enterocytes [5] and is also
involved in the delivery of iron to peripheral tissues
by transferrin [6]. Defects in the DMT1 gene cause
microcytic anemia in the mk mouse, an animal model
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2 These authors contributed equally to this work.that displays defective dietary iron absorption [7]. De-
fective transferrin-mediated iron uptake is also well
characterized for a different animal model, the Belgrade
rat, which harbors the same genetic defect in DMT1 [6].
Electrophysiological studies have shown that DMT1 not
only mediates uptake of ferrous iron, but that it also in-
teracts with other divalent metals, including Cd2+,
Co2+, Cu2+, Mn2+, Zn2+, Ni2+, and Pb2+ [8]. In addition,
the DMT1 mutation present in the b rat and mk mouse
(G185R) confers Ca2+ transport activity to the trans-
porter [9]. DMT1 activity has been characterized to be
voltage and pH dependent [8], but despite intense effort
to understand the transporter’s molecular properties
[10], relatively little is known about cellular control
of its function. To further our understanding of DMT1-
mediated iron uptake, we established a HEK293T cell
line that stably overexpresses this transporter, and we
adapted the cell-based calcein assay to screen for
small-molecule inhibitors of ferrous iron uptake in chem-
ical libraries of known bioactive compounds. Among
the inhibitors identified in this chemical genetic screen
was ebselen, an antioxidant, anti-inflammatory sele-
nium compound that has been found to be useful in
treating patients with ischemic stroke [11, 12] and
aneurismal subarachoid hemorrhage [13]. This report
characterizes inhibition of DMT1 activity by ebselen and
another unrelated antioxidant, pyrrolidine dithiocarba-
mate (PDTC). Based on these results, we propose that
DMT1 activity is inversely regulated by cellular redox
status. This study demonstrates the utility of cell-based
assays using transporter overexpression as a means of
identifying small-molecule inhibitors as well as the use-
fulness of chemical genetic screening as a tool for deter-
mining cellular factors involved in fundamental biologi-
cal processes like membrane transport.
Results
A Screen for DMT1 Transport Inhibitors
HEK293T cells were transfected with DMT1 cDNA sub-
cloned in the sense (coding) or antisense (noncoding)
orientations [14] and selected for stable expression by
using puromycin resistance. Figure 1A confirms robust
expression of the transporter in cells transfected with
sense DMT1 cDNA; DMT1 could not be detected either
in nontransfected control cells (data not shown) or
HEK293T cells transfected with antisense cDNA. Trans-
port assays to determine the uptake of 55Fe presented in
the ferrous form at pH 6.75 indicated that DMT1 activity
wasw25-fold greater in the HEK293T(DMT1) cells over-
expressing the transporter (Figure 1B). Indirect immuno-
fluorescence microscopy experiments with anti-DMT1
performed to cytolocalize exogenously expressed trans-
porters revealed cell surface as well as punctate intra-
cellular staining (Figure 1C).
Using the HEK293T(DMT1) cell line, we adapted a
cell-based screening assay for iron uptake based on cal-
cein fluorescence to identify small-molecule inhibitors
of DMT1. Briefly, the metal-sensitive fluorophore calcein
is used to measure intracellular ‘‘labile’’ or free iron. In
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Screen for Transport Inhibitors
(A) Western blot detecting DMT1 immunoreactivity in
HEK293T(DMT1) cells stably transfected with pMT2 containing
transporter’s cDNA in the sense and antisense (noncoding) orienta-
tions. Cell lysates (5 mg) were electrophoresed on a 4%–15% poly-
acrylamide gel. Proteins were transferred onto a PVDF membrane
by using a Tris-glycine transfer buffer without SDS. The membrane
was first exposed to a stripping buffer (0.2 M glycine, 0.5 M NaOH
[pH 2.8]) for 5 min, and, after blocking (Odessey Blocking Buffer, Li-
Cor Biosciences), the membrane was incubated with a 1:2000 dilu-
tion of rabbit anti-DMT1 antibodies (a kind gift of Dr. Deborah
Trinder, University of Western Australia). After washing, the blot
was incubated with a 1:10,000 dilution of goat anti-rabbit antibody
conjugated with IR-dye 800 (Rockland Immunochemicals, Inc). Af-
ter further washing, immunoreactivity was detected by infrared im-
aging (Li-Cor Odessey Infrared Imaging System). Indicated stan-
dards are Precision Plus markers (BioRad).
(B) 55Fe uptake was measured for the cell lines shown in (A). Briefly,
cells were incubated at 37C for 20 min in assay buffer containing 1
mM 55Fe and 50 mM ascorbic acid (pH 6.75). Cells were chilled on
ice and washed three times with PBS, and cell-associated radioac-
tivity was determined by scintillation counting. Shown is the aver-
age value of duplicate transport assays from a single experiment;
similar results were obtained on four separate occasions.
(C) HEK293T cells grown on lysine-coated cover slips were fixed
with 4% paraformaldehyde, blocked with 5% nonfat dry milk in
PBS, then permeabilized with 0.1% Triton X-100 and incubatedthe presence of iron or other metals, the fluorescence of
calcein is quenched [3]. Calcein does not bind to cal-
cium or magnesium at physiological pH, and since the
intracellular concentrations of other metal ions are low,
a loss of cell-associated calcein fluorescence in the
presence of extracellular iron is indicative of an increase
in free intracellular iron levels due to transport. Using
a 384-well format, 2000 compounds from the NINDS
Custom Collection and SpecPlus Collection
(Microsource Discovery Systems), available through the
Institute of Chemistry and Cell Biology at Harvard
Medical School, were robotically pin transferred and
assayed at 50 mM for the ability to block iron uptake by
HEK293T(DMT1) cells, as measured by fluorescence
quenching upon addition of 1 mM ferrous iron (nominal
cutoff for potencyR 50%).
From the survey of the 2000 bioactive compounds
contained in these 2 libraries, 23 were ‘‘cherry picked’’
and rescreened by using the calcein assay in a 384-well
format to validate results. Of these, eight compounds
were obtained from outside suppliers and further studied
by using a secondary screen for transport inhibition
based on cellular uptake of radioactive 55Fe (Figure 1D).
From this final analysis, only three compounds were
confirmed to be bona fide transport inhibitors: ebselen,
D9-tetrahydrocannabinol (THC), and 4-methoxy-dalber-
gione. Acetyl-tryptophanamide, deoxodeoxydihydro-
gendurin, and dihydromunduletone were relatively weak
inhibitors in the secondary screen, while cantharidin
appeared to slightly enhance 55Fe uptake. One other
compound, methyl 7-deshydroxypryogallin-4-carboxyl-
ate, produced a more profound stimulatory effect (data
not shown). 55Fe in the assay mixture was collected onto
filters with or without cells; therefore, the effects of this
particular compound in the screening assay were most
likely due to extracellular interactions with ferrous iron
to indirectly block uptake. Such results emphasize the
importance of secondary screens with a separate
methodological approach in validation studies.
Using the 55Fe tracer assay, ebselen andD9-THC were
determined to inhibit DMT1 activity with IC50 values
of w0.22 and 0.45 mM, respectively (Figure 2). While
4-methoxy-dalbergione also inhibited uptake, onlyabout
50% of the measured activity was blocked at concentra-
tions above 0.1 mM, suggesting that limited cell per-
meability may reduce the efficacy of this compound.
Because previous animal studies suggested that ebse-
len might affect tissue iron levels [15], our subsequent
experiments focused on characterizing its capacity to
inhibit DMT1-mediated iron uptake.
with a 1:1000 dilution of anti-DMT1 antisera. After rinsing with
PBS, cover slips were incubated with a 1:250 dilution of donkey
anti-rabbit IgG labeled with Cy3, then washed, dried, and mounted
to detect immunoreactivity by fluorescence microscopy (left, stable
HEK293T(DMT1) cells; right, nontransfected control HEK293T
cells).
(D) Secondary screen of DMT1 inhibitors by using the 55Fe uptake
assay in the presence of 50 mM of the indicated compounds or ve-
hicle alone (0.5% DMSO). Uptake was normalized to % control
(DMSO alone), and mean values (6 absolute deviation) determined
in several different experiments performed on separate occasions
(n = 4) are shown. Control values were 210.5 6 10.73 pmol 55Fe/
mg cell protein and 140.5 6 40.22 pmol/106 cells.
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DMT1 Inhibitors
HEK293T(DMT1) cells were incubated at
37C for 20 min with 0.001–100 mM of the in-
dicated compounds in the presence of 1 mM
55Fe and 50 mM ascorbic acid (pH 6.75). Cells
were chilled on ice, collected on nitrocellu-
lose filters, and washed with PBS, and cell-
associated radioactivity was determined and
normalized to control (vehicle alone). Shown
are results pooled from at least two indepen-
dent experiments with mean values 6 abso-
lute deviation (n = 4). Data were analyzed
by using a four-parameter sigmoidal model
(r2 > 0.95). The IC50 values and 95% confi-
dence intervals were 0.22 mM (0.15–0.32
mM) for ebselen and 0.45 mM (0.27–0.73 mM)
for D9-THC.Ebselen Does Not Influence DMT1 Activity
by Indirect Effects on Fe(II)
To maintain iron in the ferrous state during transport as-
says, a 50 molar-fold excess of ascorbic acid is added.
To determine if ebselen influenced DMT1-mediated
transport by altering levels of ascorbate or Fe(II) present
in the assay system, the following control experiments
were performed. First, the stability of ascorbic acid
over time was measured. The presence of 1 mM FeNTA
(1:50 complex ratio) led to a loss of ascorbic acid over
time, as measured by absorbance at 260 nm (Figure 3A).
The half-life of ascorbic acid under the same conditions
was nearly doubled by the addition of 50 mM ebselen. In
the absence of FeNTA, ascorbic acid levels were rela-
tively stable with or without the addition of ebselen.
Likewise, ebselen itself was also stable under the assay
conditions with ascorbic acid in the presence or
absence of 1 mM FeNTA (Figure 3B). Finally, the amount
of ferrous iron, measured spectrophotometrically by us-
ing the Fe(II)-specific iron chelator ferrozine (A563 nm),
was determined (Figure 3C). Fe(II) levels were stable
in the presence of ascorbic acid for 1 hr, and were fur-
ther stabilized by the presence of ebselen. Since our
transport assays to measure 55Fe(II) transport deter-
mined uptake within 20 min of the initial mixing of reac-
tion components, these combined results confirmedthat uptake of ferrous iron was measured and that
ebselen did not affect the redox state of the transport
substrate.
Ebselen Does Not Influence Fe(III) or Mn(II) Uptake
To examine whether ebselen interfered with ferric iron
transport, both transferrin bound and NTBI uptake
were measured in the presence of this inhibitor. NTBI
uptake by HeLa cells was determined as previously de-
scribed [16]. Briefly, cells were incubated at 37C with or
without ebselen in the presence of 1 mM 55FeNTA (1:4
complex) in serum-free DMEM for 1 hr. After quenching
reaction components on ice, excess unlabeled FeNTA
was added to remove any surface bound radiolabel
and cell-associated 55Fe was counted. As shown in
Figure 4A, addition of up to 100 mM ebselen did not
affect HeLa cell 55Fe uptake compared to control cells
incubated with vehicle alone (1% DMSO).
To examine whether ebselen influenced the uptake of
transferrin bound iron, apotransferrin was first loaded
with 55Fe and then incubated with cells in serum-free me-
dium for 4 hr at 37C (Figure 4B). Uptake of 55Fe from
transferrin was studied by using HeLa and HEK293T cells,
including both the parental and HEK293T(DMT1) cell
lines, as previously described [4]. The presence of up to
50 mM ebselen did not inhibit transferrin-mediated iron
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finding from these experiments was that transferrin-
mediated iron uptake was not enhanced in HEK293T(DMT1)
cells, suggesting that transferrin receptor number rather
than endosomal iron transport is limiting for iron uptake
by this pathway. Because DMT1 has a defined role in en-
dosomal transport of iron, the lack of ebselen inhibition
was also somewhat surprising. However, unlike the
DMT1 transport assays to measure Fe(II) uptake, deter-
mination of NTBI and transferrin-mediated uptake was
conducted at neutral pH. Previous studies have shown
that ebselen interactions with the thioredoxin/thiore-
doxin reductase system to reduce dehydroascorbate
are optimal at pH 6.4 [17], which is closer to the pH range
used to detect the proton-coupled DMT1 activity (pH
w6.75). It is possible that a similar pH profile modifies
the response of cellular iron uptake to ebselen, or that
this inhibitor affects factors specifically involved in me-
Figure 3. Stability of Assay Components in the Presence of
Ebselen
(A) The stability of ascorbic acid (50 mM) in the assay mixture was
determined alone (closed circle), in the presence of 50 mM ebselen
(open circles), in the presence of 50 mM ebselen and 1 mM FeNTA
(closed squares), and in the presence of 1 mM FeNTA alone (open
squares) over time by measuring absorbance at 260 nm.
(B) The stability of ebselen in the assay mixture in the presence
(closed circles) and absence (open circles) of FeNTA over time
was measured (A325 nm).
(C) The amount of ferrous iron in the assay mixture was measured
by using bathophenanthroline sulphonate (BPS) without any addi-
tion (X) or with the addition of 50 mM ascorbic acid and/or 50 mM
ebselen and was determined as indicated: ascorbic acid alone
(closed circle), ebselen alone (open circle), and ascorbic acid and
ebselen together (closed square).
Results are the mean (6SEM) of triplicate determinations.diating ferrous iron import across the cell surface, but
not endosomal membrane compartments.
DMT1 is known to transport other divalent cations in
addition to Fe(II). Compared to parental control cells,
HEK293T(DMT1) cells take up 25-fold greater levels of
54Mn, consistent with DMT1 transport of this metal (Fig-
ure 5A). Inhibition studies, however, revealed that ebse-
len did not inhibit 54Mn uptake at concentrations of up to
50 mM (Figure 5B). This result implies that inhibition of
DMT1 by ebselen is specific to the transport substrate
Fe(II). This observation is important because ebselen
can potentially modify thiols to inactivate enzymatic ac-
tivity by forming a selenylsulfide [18]. For example, the
Na+, K+-ATPase is one target for ebselen inhibition,
which occurs through the chemical modification of its
cysteine residues [19]. Consistent with the idea that
ebselen does not chemically modify DMT1 to inhibit its
Figure 4. Ebselen Does Not Inhibit Nontransferrin Bound Iron,
NTBI, or Transferrin Bound Iron, TBI, Uptake
(A) HeLa cells were plated at 300,000 cells per well. After overnight
incubation in DMEM supplemented with FBS, cells were washed
with serum-free DMEM and incubated in 1 ml of the same media
with 1 mM 55FeNTA (1:4 ratio metal:chelate) with or without the in-
dicated concentrations of ebselen for 1 hr. Cells were chilled on
ice, washed in PBS++, and then incubated with quench buffer con-
taining 1 mM FeNTA for 1 hr on ice. After washing with PBS++, cells
were lysed, and cell-associated radioactivity was determined by
scintillation counting and was normalized to cell protein.
(B) HeLa, control HEK293T, or HEK293T(DMT1) cells were plated as
described for (A), except that 800,00 cells per well were used for
the latter two cell lines. Uptake assays were performed in serum-
free DMEM containing 40 nM 55Fe-Tf in the presence or absence
of 1, 10, or 50 mM ebselen. Cells were incubated for 4 hr, then chilled
on ice and incubated with a quench buffer containing 1 mM unlabeled
Tf for 1 hr. After washing with PBS++, cells were lysed, and cell-
associated radioactivity was determined and normalized to cell
protein.
Results shown in both panels are the means (6 absolute deviation)
from at least two independent studies (n = 4).
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969transport activity, the addition of dithiothreitol (DTT) as
a reducing agent did not reverse ebselen’s effects on
Fe(II) uptake (data not shown). Moreover, inhibition of
Figure 5. Ebselen Inhibits Fe(II), but Not Mn(II), Uptake and Acts in
a Reversible Manner
(A) 54Mn uptake was measured for control HEK293T and
HEK293T(DMT1) cells. The average value for uptake calculated as
pmol 54Mn/mg protein from a single experiment performed in dupli-
cate is shown; similar results were obtained on a separate occasion.
(B) Uptake studies were performed to compare inhibition of Fe(II)
and Mn(II) uptake by ebselen. Assay conditions were the same as
in Figure 2, except that 1 mM 55FeNTA or 1 mM 54MnCl2 was added
to the transport reaction mixtures containing 50 mM ebselen or
vehicle alone (0.5% DMSO). Uptake was normalized to control
values, which were 128.11 6 19.32 pmol 55Fe/106 cells and 51.39 6
21.61 pmol 54Mn/106 cells.
(C) The reversibility of transport inhibition was determined by first in-
cubating HEK293T(DMT1) cells with either 0.01% DMSO or 1 mM eb-
selen for 20 min in PBS++, then washing the cells three times with
PBS++, and allowing a recovery period of 30 min at 37C in PBS++
containing 5 mM glucose. Subsequently, 55Fe uptake was measured
by adding 1 mM ebselen or vehicle back to the reaction mixtures.
Uptake was normalized to control cells (pretreated with DMSO and
assayed in the presence of DMSO).
Results shown in (B) and (C) are mean values (6 absolute deviation)
determined in two independent experiments (n = 4).Fe(II) uptake by ebselen was fully reversed after treat-
ment of cells and subsequent wash out of the drug
(Figure 5C).
PDTC Inhibits DMT1-Mediated Fe(II) Uptake
Because ebselen appeared to target the pathway of
Fe(II) uptake rather specifically, we reasoned that the
antioxidant effects of this compound might influence
transport of this redox-active metal. We therefore stud-
ied another antioxidant, PDTC, which is structurally un-
related to ebselen. This antioxidant is commonly used to
probe redox-sensitive NF-kB activation in vivo [20–22].
Inhibition studies demonstrated that PDTC inhibited
DMT1 55Fe transport activity (Figure 6). The IC50 was
determined to be 1.54 mM, although it should be noted
that the 95% confidence interval for this value is large
(0.68–3.45 mM). To directly compare the effects of both
ebselen and PDTC on cellular glutathione levels, the
ratio of reduced to oxidized glutathione was measured
in HEK293T(DMT1) cells treated with 10 mM ebselen,
50 mM PDTC, or 0.5 % DMSO (vehicle control) for
20 min at 37C under the transport assay conditions.
The GSSG, GHS + GSSG, and GSH/GSSG values deter-
mined in these experiments are summarized in Table 1.
Both compounds increased cellular levels of reduced
GSH, as anticipated based on their antioxidant capacity.
A simple interpretation of these combined results is that
DMT1-mediated Fe(II) uptake activity is modulated by
cellular redox status.
Discussion
The use of small molecules to alter cellular function pro-
vides new opportunities to determine mechanistic ele-
ments involved in complex biological pathways. While
molecular genetic approaches have provided new in-
sights into iron transport, such as the identification of the
iron transporter DMT1 [7, 8], there is a significant need
to develop pharmacological tools to gain further insight
into the molecular basis of metal uptake and regula-
tion. To discover small-molecule inhibitors of DMT1-
mediated transport activity, we established a phenotypic
screen based on calcein fluorescence quenching in a
cell-based assay for iron uptake. Use of the stable
HEK293T(DMT1) cell line provided the necessary
Figure 6. Antioxidant Activity Inhibits DMT1-Mediated Iron Uptake
Inhibition of 55Fe uptake by HEK293T(DMT1) cells was determined
in the presence of 0.001–100 mM PDTC, an antioxidant that is struc-
turally unrelated to ebselen. Shown are mean values (6 absolute
deviation) from data collected in two different experiments (n = 4).
Dose response was analyzed by using a four-parameter sigmoidal
model (r2 = 0.94).
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amplified and sensitive manner. This report demon-
strates the utility of this cell-based approach in a screen
of 2000 known bioactive compounds. Two potent trans-
port inhibitors were identified: ebselen (IC50 of w0.22
mM) and D9-THC (IC50 ofw0.47 mM). D
9-THC, the major
psychoactive component of the marijuana plant Canna-
bis sativa, is known to produce a number of behavioral
and pharmacological effects mediated through inter-
actions with the central nervous system cannabinoid
receptor CB1 and the peripheral receptor CB2. Endoge-
nous cannabinoids also activate these G protein-
coupled receptors to negatively regulate adenylate cy-
clase activity and positively regulate inward rectifying
K+ channels [23]. It is interesting to note that receptor-
independent signal transduction pathways have also
been recently reported to negatively regulate a number
of ion channels, including T-type Ca2+ channels, TASK-1
channels, and Na+ channels [24]. There is significant in-
terest in identifying signaling targets for cannabinoids
since drugs that modify endocannabinoid activity are
currently being developed to control obesity (Rimona-
bant), prevent osteoporosis (HU-308), and treat multiple
sclerosis (Sativex). Marinol (pure THC) is still often used
in treating AIDS and cancer patients. Thus, future studies
must address both the mechanism of DMT1 inhibition by
D9-THC as well as the significance of these effects.
Our immediate efforts focused on defining how ebse-
len affected DMT1-mediated iron uptake. Ebselen (also
called PZ51), or 2-phenyl-1,2-benzisoselenazol-3[2H]-
one, is thought to exert antioxidant effects as a glutathi-
one peroxidase mimic (reviewed by Schewe [18]). More
recent studies have shown that ebselen rapidly oxidizes
reduced thioredoxin to interact with the thioredoxin re-
ductase system [25, 26]. Ebselen is also known to di-
rectly inhibit several inflammatory enzymes by thiol
modification to form a selenosulfide [18]. Interestingly,
previous in vivo studies have demonstrated that ebselen
treatment is associated with reduced tissue iron in
a model of iron overload, suggesting its potential inhibi-
tion of iron uptake [15]. Although the antioxidant, anti-in-
flammatory actions of ebselen provide a mechanistic
explanation for its efficacy in clinical trials, many animal
studies have shown that iron chelation also successfully
limits damage in models of ischemic stroke [27], consis-
tent with the idea that ebselen could act therapeutically
by inhibiting tissue iron uptake.
A previous study of DMT1 activity with Xenopus
oocytes suggested that oxidative agents could inhibit
Table 1. Antioxidant Effects on GSH/GSSG Ratio
GSSG GSH + GSSG GSH/GSSG
0.5% DMSO (n = 13) 0.73 6 0.15 40.52 6 4.35 56.42 6 9.11
10 mM ebselen (n = 10) 0.49 6 0.15a 37.11 6 3.31 81.65 6 20.1a
50 mM PDTC (n = 13) 0.62 6 0.05a 40.79 6 5.85 65.14 6 6.77a
GSSG equivalents (nmol/million cells) were determined by using
the GSH/GSSG-412 kit as described by the manufacturer (Oxis-
Research, Portland, OR). Five million cells were assayed per point,
and measurements were made by using a microtiter plate (405 nm).
Shown are the mean values 6 absolute deviation determined in five
independent experiments.
a Different from control (0.5% DMSO); p < 0.05.transporter function by direct modification of protein
thiols [28]. Both zinc and iron uptake were blocked by
treatment with H2O2 and Hg
2+, and DMT1-mediated
transport activity was restored by the addition of DTT.
We find that ebselen’s influence on DMT1 function is un-
likely to be mediated by such direct effects on this trans-
porter since the compound failed to block uptake of
DMT1-mediated manganese and DTT failed to reverse
inhibition of DMT1-mediated iron uptake. There are at
least two possible explanations for how changes in cel-
lular redox might promote inhibition of ferrous iron in
a specific manner. First, the reduced cellular environ-
ment promoted by ebselen and PDTC could allow an ex-
pansion in the ‘‘labile’’ or free iron pool under our assay
conditions. The total concentration of cytosolic free iron
is balanced between Fe(II) and Fe(III), and the ratio of
these forms is known to be determined by the cellular
redox capacity [29, 30]. The antioxidants also may influ-
ence the activity of other factors known to modulate in-
tracellular levels of free divalent iron, for example, ferric
reductases [31]. Mathematical modeling of the mecha-
nisms of DMT1-mediated transport [32] suggests that
carrier-mediated uptake of Fe(II) into the cell could be-
come limiting when intracellular concentrations of the
transport substrate increased. Alternatively, the anti-
oxidants could possibly influence the activity of specific
factors involved in the intracellular targeting of Fe(II) to
fulfill specific metabolic functions, for example, transfer
to mitochondria for heme synthesis or iron-sulfur cluster
formation [33]. This scenario is based on analogy to the
family of copper chaperones that mediate movement of
this metal throughout the cell to achieve metabolic tar-
geting after import [34]. The discovery of ebselen’s
inhibitory effects sheds new light on how the cellular re-
dox environment can influence iron uptake. Use of anti-
oxidants like ebselen and PDTC as pharmacological in-
hibitors of DMT1-mediated iron uptake should help to
provide further molecular insights into the pathway’s
cellular factors involved in this process.
Significance
There is a significant need to develop pharmacological
tools to gain further insight into the molecular basis
for iron uptake and its regulation. To develop a cell-
based screen for inhibitors, a stable HEK293T(DMT1)
cell linewasestablished todetectDMT1Fe(II) transport
activity in an amplified and sensitive manner. Using
calcein fluorescence quenching to assay ferrous iron
transport inhibition, 2000 knownbioactive compounds
were screened and 3 potent transport inhibitors were
identified. This report further characterizes the activity
of one of these inhibitors, ebselen. This seleno com-
pound is a protective agent against ischemic stroke.
Ebselen inhibited Fe(II) uptake (IC50 of w0.22 mM),
but did not influence Fe(III) or DMT1-mediated manga-
nese uptake. Studies with an unrelated antioxidant,
PDTC, confirmed that the cellular redox environment
influences DMT1 iron uptake activity. Future use of
antioxidants like ebselen and PDTC as pharmacologi-
cal inhibitors of DMT1-mediated iron uptake should
help toprovide furthermolecular insights into thepath-
way’s cellular factors involved in this process.
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Generation of a Stable DMT1 Cell Line
HEK293T cells were grown to 60% confluency in Dulbecco’s modi-
fied Eagle’s medium (DMEM) containing 50 U/ml penicillin, 50 mg/ml
streptomycin, 2 mM L-glutamine, and 10% fetal bovine serum. The
cells were cotransfected with pMT2-Nramp2 in a coding (sense) or
noncoding (antisense) orientation (a kind gift from Dr. Nancy
Andrews) and pBABEPuro (carrying a puromycin-resistance gene)
at a 20:1 ratio by using Effectine (QIAGEN) according to the manu-
facturer’s instructions. After allowing 48 hr for gene expression,
selection was performed by adding 2 mg/ml puromycin to the culture
medium. After stable selection under these restrictive growth condi-
tions, cells were subsequently grown in a minimal essential medium
(aMEM) supplemented with 50 U/ml penicillin, 50 mg/ml strepto-
mycin, and 10% fetal bovine serum.
Small-Molecule Library Screen
HEK293T(DMT1) cells were plated in 384-well poly-D-lysine-coated
plates (Becton Dickinson) in columns 1–23 (15,000 cells/well) by
using a Wellmate liquid dispensing apparatus (Matrix Technologies
Corp.). Column 24 was left empty. After overnight incubation, the
plates were washed three times with 65 ml serum- and phenol red-
free aMEM by using a Bio-Tek ELx405 plate washer. Calcein-AM
was added to a final concentration of 0.25 mM. After a 1 hr incubation
at 37C, the plates were washed ten times with 65 ml phosphate-
buffered saline containing 1 mM MgCl2 and 0.1 mM CaCl2 (PBS++)
with 5 mM glucose added. A final volume of 40 ml of this same buffer
was added to each well, and a baseline fluorescence reading was
measured by using an Analyst plate reader (485 nm excitation;
535 nm emission; Molecular Devices Corp.). Using a robotic pin-
transfer apparatus, w250 nl of each compound was transferred
from master plates to duplicate HEK293T(DMT1) plates, which
were then incubated at 37C for 30 min, after which time a second
fluorescence reading was taken. To each well in column 1, 10 ml
aliquots of 200 mM HEPES, 200 mM Tris (pH 6.0), and 250 mM ascor-
bic acid were added. To each well in columns 2–24, 10 ml of the same
assay mix with 5 mM FeNTA (1:50 metal:chelate ratio) was added.
Columns 1 and 2 were used as controls, and no compounds were
transferred to these wells. The plates were incubated at 37C for
an additional 20 min, and a final fluorescence reading was taken.
Inhibition Studies with Radioisotopic Tracer
HEK293T(DMT1) cells were incubated at 37C for 20 min in assay
buffer (25 mM Tris, 25 mM MES, 140 mM NaCl, 5.4 mM KCl,
1.8 mM CaCl2, 0.8 mM MgSO4, 5 mM glucose [pH 6.75]) containing
1 mM 55Fe or 54Mn and 50 mM ascorbic acid (pH 6.75) (05–1.5 3 106
cells/transport reaction). Inhibitors were added at the concentra-
tions noted in the figure legends immediately prior to the start of
uptake. Cells were chilled on ice and either collected on nitrocellu-
lose filters or by centrifugation at 2040 3g for 5 min, then washed
three times with PBS to remove any unbound 55Fe or 54Mn. Cell-
associated radioactivity was determined by scintillation counting
and was normalized to control (vehicle alone) or adjusted to cell pro-
tein measured in lysates by using the Bradford assay [35]. Values
reported in figures and the text are means 6 absolute deviation
unless otherwise noted.
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